Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton, Jr. Acquires 49,036 Shares of Company Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. acquired 49,036 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was bought at an average price of $2.69 per share, with a total value of $131,906.84. Following the purchase, the director directly owned 1,046,003 shares in the company, valued at approximately $2,813,748.07. This trade represents a 4.92% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Anixa Biosciences Stock Performance

Shares of Anixa Biosciences stock opened at $2.78 on Friday. The business has a 50-day simple moving average of $3.24 and a 200-day simple moving average of $2.97. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46. The company has a market cap of $96.63 million, a PE ratio of -8.69 and a beta of 0.51.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). On average, sell-side analysts predict that Anixa Biosciences Inc will post -0.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ANIX shares. HC Wainwright decreased their price objective on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. D. Boral Capital restated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC purchased a new position in Anixa Biosciences during the 2nd quarter worth approximately $29,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Integrated Wealth Concepts LLC purchased a new stake in Anixa Biosciences in the second quarter valued at approximately $30,000. Simplicity Wealth LLC purchased a new stake in Anixa Biosciences in the second quarter valued at approximately $34,000. Finally, NewEdge Wealth LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $35,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.